abstract |
FIELD: medicine. n SUBSTANCE: group of inventions relates to therapy and endocrinology, and to the use of long-acting GLP-1 peptides for the treatment of obesity. For this, 0.7 mg semaglutide is administrated per week as a monotherapy. n EFFECT: this provides the most effective weight loss in comparison with the action of other GLP-1 receptor agonists. n 22 cl, 5 dwg, 1 tbl, 1 ex |